Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 16666.67 iu/ml - injection - excipient ingredients: threonine; polysorbate 20; urea; water for injections; dibasic sodium phosphate dodecahydrate; glutamic acid; leucine; sodium chloride; calcium chloride dihydrate; monobasic sodium phosphate; phenylalanine; glycine; isoleucine - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 20000 iu/ml - injection - excipient ingredients: polysorbate 20; monobasic sodium phosphate; sodium chloride; urea; isoleucine; glycine; threonine; calcium chloride dihydrate; glutamic acid; dibasic sodium phosphate dodecahydrate; phenylalanine; leucine; water for injections - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 16666.67 iu/ml - injection - excipient ingredients: glutamic acid; leucine; isoleucine; polysorbate 20; water for injections; dibasic sodium phosphate dodecahydrate; urea; monobasic sodium phosphate; phenylalanine; threonine; calcium chloride dihydrate; glycine; sodium chloride - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 13333.33 iu/ml - injection - excipient ingredients: leucine; phenylalanine; polysorbate 20; glycine; urea; water for injections; sodium chloride; calcium chloride dihydrate; monobasic sodium phosphate; threonine; glutamic acid; isoleucine; dibasic sodium phosphate dodecahydrate - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 10000 iu/ml - injection - excipient ingredients: monobasic sodium phosphate; glycine; polysorbate 20; leucine; threonine; water for injections; isoleucine; calcium chloride dihydrate; phenylalanine; urea; glutamic acid; dibasic sodium phosphate dodecahydrate; sodium chloride - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 6666.66 iu/ml - injection - excipient ingredients: calcium chloride dihydrate; dibasic sodium phosphate dodecahydrate; water for injections; glutamic acid; isoleucine; urea; monobasic sodium phosphate; polysorbate 20; glycine; phenylalanine; leucine; sodium chloride; threonine - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

United States - English - NLM (National Library of Medicine)

university of texas md anderson cancer center - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - hematopoietic progenitor cell (hpc), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the benefit-risk assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. risk summary there are no data with hpc, cord blood use in pregnant women to inform a product-associated risk.  animal reproduction studies have not been conducted with hpc, cord blood. in the u.s. general population, the estimated background risk of major birth defects and misc

Singapore - English - HSA (Health Sciences Authority)

livanova singapore pte ltd - general hospital - disposable autotransfusion set containing tubing, wash set, collection set, etc.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - deferasirox - iron overload; beta-thalassemia - all other therapeutic products, iron chelating agents - deferasirox accord is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.deferasirox accord is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

moraf pharmaceuticals limited, tanzania - blood collection tube -